These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 22923346)

  • 1. Molecular chaperones, α-synuclein, and neurodegeneration.
    Witt SN
    Mol Neurobiol; 2013 Apr; 47(2):552-60. PubMed ID: 22923346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
    Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
    Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease.
    Lo Bianco C; Shorter J; Régulier E; Lashuel H; Iwatsubo T; Lindquist S; Aebischer P
    J Clin Invest; 2008 Sep; 118(9):3087-97. PubMed ID: 18704197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropathology of synuclein aggregates.
    Duda JE; Lee VM; Trojanowski JQ
    J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional deficiencies in chaperone-mediated autophagy underlie α-synuclein aggregation and neurodegeneration.
    Malkus KA; Ischiropoulos H
    Neurobiol Dis; 2012 Jun; 46(3):732-44. PubMed ID: 22426402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-synuclein aggregation and its modulation.
    Ghosh D; Mehra S; Sahay S; Singh PK; Maji SK
    Int J Biol Macromol; 2017 Jul; 100():37-54. PubMed ID: 27737778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
    Uversky VN
    J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond neurodegenerative diseases: α-synuclein in erythropoiesis.
    Ling L; Wang F; Yu D
    Hematology; 2022 Dec; 27(1):629-635. PubMed ID: 35621991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Munc18-1 is a molecular chaperone for α-synuclein, controlling its self-replicating aggregation.
    Chai YJ; Sierecki E; Tomatis VM; Gormal RS; Giles N; Morrow IC; Xia D; Götz J; Parton RG; Collins BM; Gambin Y; Meunier FA
    J Cell Biol; 2016 Sep; 214(6):705-18. PubMed ID: 27597756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between calcium and alpha-synuclein in neurodegeneration.
    Rcom-H'cheo-Gauthier A; Goodwin J; Pountney DL
    Biomolecules; 2014 Aug; 4(3):795-811. PubMed ID: 25256602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70.
    Batelli S; Albani D; Rametta R; Polito L; Prato F; Pesaresi M; Negro A; Forloni G
    PLoS One; 2008 Apr; 3(4):e1884. PubMed ID: 18382667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies.
    Ebrahimi-Fakhari D; Saidi LJ; Wahlster L
    Acta Neuropathol Commun; 2013 Dec; 1(1):79. PubMed ID: 24314025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease.
    Park JY; Paik SR; Jou I; Park SM
    Glia; 2008 Aug; 56(11):1215-23. PubMed ID: 18449945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation.
    Oh Y
    BMB Rep; 2019 Jun; 52(6):349-359. PubMed ID: 31186086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
    Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
    Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
    Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
    J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PMR1 pump in alpha-synuclein toxicity and neurodegeneration.
    Nikoletopoulou V; Tavernarakis N
    Neurosci Lett; 2018 Jan; 663():66-71. PubMed ID: 28780169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.